Bird Rock Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bird Rock Bio, Inc. - overview
Established
2006
Location
-, CA, US
Primary Industry
Pharmaceuticals
About
Establised in 2006 and based in California, US, Bird Rock Bio is a clinical-stage biopharmaceutical company that offers antibody therapeutics for immuno-inflammatory diseases. In August 2023, Skye Bioscience, Inc. portfolio company of 5AM Ventures and Versant Ventures acquired Bird Rock Bio for USD 20 million. Bird Rock Bio’s pipeline centered around Nimacimab, a therapeutic antibody designed to modulate immune and metabolic pathways.
The company also developed a broader portfolio of monoclonal antibodies targeting G-protein coupled receptors (GPCRs), leveraging its proprietary discovery platform. These biologics were designed to offer improved specificity and efficacy over traditional small molecule drugs.
Current Investors
5AM Ventures, Versant Ventures, SR One
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Bird Rock Bio, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Director of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.